glp-1 receptor agonists cardiovascular benefits for the Reduction of Atherosclerotic Risk in Patients With Type 2 Diabetes GLP-1 Receptor Agonists in the

But here is a silver lining

Downregulating the expression of miR-23a and increasing the expression of the mitochondrial protective gene peroxisome proliferators-activated receptor- coactivator-1 (PGC-1) can exert an anti-apoptotic effect on human hepatocytes [34]

The current generation of GLP-1 receptor agonists includes: Semaglutide (weekly subcutaneous injection or oral formulation) Liraglutide (daily subcutaneous injection) Tirzepatide (dual GLP-1/GIP receptor agonist, weekly subcutaneous injection) Each of these GLP-1 agents carries a distinct pharmacological profile, and the optimal choice depends on a patients clinical history, metabolic risk factors, and therapeutic goals a determination best made in consultation with a physician experienced in metabolic and longevity medicine

Some experts, however, expressed concerns about the platform and raised questions about Lillys financial motives

doi: 10.1152/ajpregu.00444.2015, 96 Matikainen-AnkneyB

We conducted the TSA with an overall 5% risk of type I error and 20% risk of type II error (power of 80%)